Please wait a minute...
Reviews in Cardiovascular Medicine  2015, Vol. 16 Issue (1): 9-19     DOI: 10.3909/ricm0719
Previous articles | Next articles
The Mystery of High-density Lipoprotein: Quantity or Quality? Update on Therapeutic Strategies
Vasiliki Katsi1, Manolis S. Kallistratos2, Antonios N. Pavlidis3, Nikos Karpettas4, Ioannis Skoumas5, Nikonas Pavleros1, Athanasios J. Manolis2, Christos Pitsavos5, Dimitris Tousoulis5, Christodoulos Stefanadis5, Ioannis Kallikazaros1
1 Department of Cardiology, Hippokration Hospital, Athens, Greece
2 Department of Cardiology, Asklepeion General Hospital, Athens, Greece
3 Department of Cardiology, London Chest Hospital, London, United Kingdom
4 Hypertension Center, Third University Department of Medicine, Athens Medical School, Sotiria Hospital, Athens, Greece
5 First Cardiology Department, Athens University Medical School, Athens, Greece
Download:  PDF(304KB)  ( 162 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
This review summarizes the data challenging the concept that cardiovascular protection through high-density lipoprotein (HDL) is only associated with its serum concentration. This conventional impression about its protective role now appears obsolete. New aspects of its mechanisms are revealed and novel therapeutic strategies are based on them. However, data from long-term cost-effectiveness studies of treating HDL are still needed. There is a need for biomarkers that represent the functional characteristics of HDL in order to better quantify the total cardiovascular risk.
Key words:  Apolipoprotein A-I      Cardiovascular protection      Dyslipidemia      High-density lipoprotein      Risk factors     
Published:  30 March 2015     

Cite this article: 

Vasiliki Katsi, Manolis S. Kallistratos, Antonios N. Pavlidis, Nikos Karpettas, Ioannis Skoumas, Nikonas Pavleros, Athanasios J. Manolis, Christos Pitsavos, Dimitris Tousoulis, Christodoulos Stefanadis, Ioannis Kallikazaros. The Mystery of High-density Lipoprotein: Quantity or Quality? Update on Therapeutic Strategies. Reviews in Cardiovascular Medicine, 2015, 16(1): 9-19.

URL: 

https://rcm.imrpress.com/EN/10.3909/ricm0719     OR     https://rcm.imrpress.com/EN/Y2015/V16/I1/9

[1] Jun Zhang, Natalia de Albuquerque Rocha, and Peter A. McCullough. Contribution of ApoCIII to Diabetic Dyslipidemia and Treatment With Volanesorsen[J]. Reviews in Cardiovascular Medicine, 2018, 19(1): 13-19.
[2] Boback Ziaeian, John Dinkler, Karol Watson. Implementation of the 2013 American College of Cardiology/American Heart Association Blood Cholesterol Guideline Including Data From the Improved Reduction of Outcomes: Vytorin Efficacy International Trial[J]. Reviews in Cardiovascular Medicine, 2015, 16(2): 125-130.
[3] Virginia A. Triant. Epidemiology of Coronary Heart Disease in Patients With Human Immunodeficiency Virus[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 1-8.
[4] Giovanni Guaraldi, Antonella Santoro, Chiara Stentarelli, Kety Luzi. Impact of Antiretroviral Medications on Fasting Lipid Parameters[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 30-37.
[5] Peter Shalit. Management of Dyslipidemia in Patients With Human Immunodeficiency Virus[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 38-46.
[6] Peter A. McCullough, Amina B. Ahmed, Marc T. Zughaib, Eric D. Glanz, Michael J. Di Loreto. Treatment of Hypertriglyceridemia With Fibric Acid Derivatives: Impact on Lipid Subfractions and Translation Into a Reduction in Cardiovascular Events[J]. Reviews in Cardiovascular Medicine, 2011, 12(4): 173-185.
[7] Prediman K. Shah. Residual Risk and High-Density Lipoprotein Cholesterol Levels: Is There a Relationship?[J]. Reviews in Cardiovascular Medicine, 2011, 12(2): 55-59.
[8] Ashley Simmons, Jillian Falbe, James Vacek. Coronary Artery Disease in Women: A Review and Update[J]. Reviews in Cardiovascular Medicine, 2011, 12(2): 84-93.
[9] Gustavo A. Cardenas, Carl J. Lavie, Vanessa Cardenas, Richard V. Milani, Peter A. McCullough. The Importance of Recognizing and Treating Low Levels of High-Density Lipoprotein Cholesterol: A New Era in Atherosclerosis Management[J]. Reviews in Cardiovascular Medicine, 2008, 9(4): 239-258.
[10] Karol E. Watson. Novel Therapies for Cardiometabolic Risk Reduction and Implications for Clinical Practice[J]. Reviews in Cardiovascular Medicine, 2007, 8(S4): 37-42.
[11] Stuart W. Zarich. Cardiovascular Risk Factors in the Metabolic Syndrome: Impact of Insulin Resistance on Lipids, Hypertension, and the Development of Diabetes and Cardiac Events[J]. Reviews in Cardiovascular Medicine, 2005, 6(4): 194-205.
[12] . Best of the AHA Scientific Sessions 2004[J]. Reviews in Cardiovascular Medicine, 2005, 6(1): 33-46.
[13] Karol E. Watson, Eric J. Topol. Pathobiology of Atherosclerosis: Are There Racial and Ethnic Differences?[J]. Reviews in Cardiovascular Medicine, 2004, 5(S3): 14-21.
[14] Keith C. Ferdinand, Keith C. Ferdinand. The Epidemic of Diabetes Mellitus and the Metabolic Syndrome in African Americans[J]. Reviews in Cardiovascular Medicine, 2004, 5(S3): 28-33.
[15] . Best of the AHA Scientific Sessions 2003[J]. Reviews in Cardiovascular Medicine, 2004, 5(1): 26-52.
No Suggested Reading articles found!